CPE News (8/28/2020) – CAIAC Fund Management AG disclosed that Biotech Opportunity Fund, a Liechtenstein-based Alternative Investment Fund managed by CAIAC, has acquired control and direction over, ownership of, an aggregate of 26,363,172 common shares in the capital of Helix BioPharma Corp. (TSX: HBP), effective on August 27, 2020, in an off-shore transaction.
Biotech Opportunity Fund paid approximately CDN $0.50 per share for the acquired shares for an aggregate consideration of approximately CDN $13,181,586.
Immediately before giving effect to the share acquiistion, CAIAC did not own, or have control or direction over, any securities of Helix BioPharma. Following the acquisition, CAIAC exercises control and direction over 26,363,172 common shares, representing approximately 19.83% of Helix Biopharma’s issued and outstanding common shares on a non-diluted basis.
Bendern, Liechtenstein based CAIAC Fund Management did not disclose the name of the seller or the names of the sellers.
As of October 24, 2019, Jerzy Wilczewski was the single largest shareholder of Helix Biopharma, controlling 19,617,153 common shares or 15.70% of the outstanding shares.
With the share acquisition, Biotech Opportunity Fund becomes the largest shareholder of Helix Biopharma.
Richmond Hill, Ontario based Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (CAR) based cell therapies.
photo credit: Helix BioPharma
CAIAC FUND MANAGEMENT AG ACQUIRES SECURITIES OF HELIX BIOPHARMA CORP.
August 28, 2020 (Liechtenstein) – CAIAC Fund Management AG (“CAIAC”), as portfolio manager for Biotech Opportunity Fund, a Liechtenstein-based Alternative Investment Fund regulated by the Financial Market Authority of Liechtenstein (the “Fund”) announces, pursuant to the Canadian early warning requirements, that on August 27, 2020, it acquired control and direction over, and the Fund acquired ownership of, an aggregate of 26,363,172 common shares (the “Common Shares”) in the capital of Helix BioPharma Corp. (the “Issuer”), in an off-shore transaction (the “Transaction”). The Common Shares were acquired for consideration valued at approximately CAD $0.50 per Common Share, and aggregate consideration value equal to approximately CAD $13,181,586.
Immediately before giving effect to the Transaction, CAIAC did not own, or have control or direction over, any securities of the Issuer. As a result of the Transaction, CAIAC exercises control and direction over the aforementioned Common Shares, which are owned by the Fund and which represents approximately 19.83% of the Issuer’s issued and outstanding Common Shares on a non-diluted basis.
CAIAC does not itself own any securities of the Issuer, but has authority to exercise control or direction over securities of the Issuer that are held by the Fund. The Common Shares were acquired for investment purposes and not for the purpose of exercising control or direction over the Issuer. CAIAC may, depending on market and other conditions, increase or decrease the Fund’s ownership of Common Shares, through market transactions, private agreements or otherwise.
This press release is issued pursuant to the early warning requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and National Instrument 62-104 – Take-Over Bids and Issuer Bids of the Canadian Securities Administrators, which also requires an Early Warning Report to be filed with applicable Canadian securities regulatory authorities containing additional information in respect of the foregoing matters. A copy of the Early Warning Report will appear under the Issuer’s profile on the SEDAR website at www.sedar.com. A copy of the Early Warning Report may also be obtained upon request at the contact details below.
CAIAC Fund Management AG
Principality of Liechtenstein
Contact: Thorsten Schüttke
Source: Private Capital Journal